Poster on effects of new antidiabetic drugs on cardiovascular health
This poster summarizes cardiovascular outcome trials of newly developed glucose-lowering agents. Some of these drugs have shown cardiovascular benefit that might have clinical importance in the management of type 2 diabetes.
Obese individuals with more components of the metabolic syndrome and/or prediabetes demonstrate decreased activation of reward-related brain centers in response to food cues in both the fed and fasting states: a preliminary fMRI study
O M Farr and C S Mantzoros
Int J Obes 2017 41: 471-474; advance online publication, December 26, 2016; 10.1038/ijo.2016.231
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact email@example.com
Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to International Journal of Obesity. In order to do so, please purchase a subscription.
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).